首页|二甲双胍对胰腺癌细胞吉西他滨耐药及Hippo/YAP通路的影响

二甲双胍对胰腺癌细胞吉西他滨耐药及Hippo/YAP通路的影响

扫码查看
目的 分析二甲双胍对胰腺癌CFPAC-1细胞吉西他滨化疗敏感性的影响,并探讨可能的作用机制.方法 体外培养人胰腺癌CFPAC-1细胞、吉西他滨耐药株CFPAC-1/吉西他滨细胞,MTT法检测不同浓度(0、1.0、2.5、5.0、10.0、20.0、40.0 mmol/L)二甲双胍、不同浓度(0、50、100、150、200、250 µmol/L)吉西他滨对 CFPAC-1 细胞、CFPAC-1/吉西他滨细胞存活率的影响,筛选无细胞毒作用的二甲双胍浓度、计算吉西他滨的药物半数抑制浓度(IC50);MTT法检测2.5 mmol/L二甲双胍与不同浓度(0、50、100、150、200、250 μmol/L)吉西他滨联用对CFPAC-1细胞、CFPAC-1/吉西他滨细胞存活率的影响,计算二甲双胍的IC50及耐药逆转倍数;采用流式AnnexinV-FITC/PI双染法检测以吉西他滨的1C50为该药浓度,吉西他滨单用、2.5 mmol/L二甲双胍+吉西他滨联用处理对CFPAC-1细胞、CFPAC-1/吉西他滨细胞凋亡率的影响并采用免疫印迹法检测细胞Hippo/YAP通路相关蛋白(MSTl/2、LASTl/2、YAP、p-YAP)相对表达量.结果 与0 mmol/L二甲双胍比较,10.0、20.0、40.0 mmol/L二甲双胍处理的CFPAC-1、CFPAC-1/吉西他滨细胞存活率显著降低,差异均有统计学意义(F=15.632、20.958,P均<0.001).随吉西他滨浓度增加,CFPAC-1、CFPAC-1/吉西他滨细胞存活率下降,CFPAC-1/吉西他滨细胞对吉西他滨的IC50[(93.35±5.12)μmol/Lvs.(217.87±11.34)μmol/L]显著高于 CFPAC-1 细胞,差异有统计学意义(t=24.514,P<0.05).CFPAC-1/吉西他滨细胞耐药指数为2.33.2.5 mmol/L二甲双胍与不同浓度吉西他滨联用后,CFPAC-1细胞的IC50(76.53±3.65)μmol/L 比吉西他滨单用时(93.35±5.12)μmol/L 低(t=6.552,P<0.05),CFPAC-1/吉西他滨细胞的 IC50(171.65±6.89)µmol/L比吉西他滨单用时(217.87±11.34)μmol/L低(t=8.532,P<0.05),差异均有统计学意义.CFPAC-1/吉西他滨细胞对吉西他滨耐药逆转倍数为1.26.与对应的吉西他滨组比较,药物联用组CFPAC-1/吉西他滨细胞凋亡率、MST1/2、LAST1/2、p-YAP/YAP 表达均显著升高,差异均有统计学意义(F=53.798、35.585、14.512、25.525,P均<0.001).结论 二甲双胍可一定程度增加CFPAC-1/吉西他滨细胞对吉西他滨的化疗敏感性,机制可能与激活Hippo/YAP通路有关.
Effects of metformin on gemcitabine resistance and Hippo/YAP pathway in pancreatic cancer cells
Objective To analyze the impact of metformin(Met)on the chemotherapy sensitivity of gemcitabine(GEM)in CFPAC-1 cells of pancreatic cancer,and explore the possible mechanism.Methods Human pancreatic cancer CFPAC-1 cells and gemcitabine-resistant CFPAC-1/gemcitabine cells were cultured in vitro.The MTT method was used to detect the effects of different concentrations(0,1.0,2.5,5.0,10.0,20.0,40.0 mmol/L)of metformin and different concentrations(0,50,100,150,200,250 μmol/L)of gemcitabine on the survival rates of CFPAC-1 cells and CFPAC-1/gemcitabine cells.The metformin concentration without cytotoxicity was screened and the half inhibitory concentration(IC50)of gemcitabine was calculated.The MTT method was used to detect the inhibitory effect of 2.5 mmol/L metformin on the survival rate of CFPAC-1 cells and CFPAC-1/gemcitabine cells.The effects of metformin and gemcitabine on the survival rate of CFPAC-1 cells and CFPAC-1/gemcitabine cells were analyzed by flow cytometry.The IC50 of metformin and the reversal fold of drug resistance were calculated.The flow cytometry AnnexinV-FITC/PI double staining method was used to detect the effects of gemcitabine alone and 2.5 mmol/L metformin+gemcitabine on the apoptosis rate of CFPAC-1 cells and CFPAC-1/gemcitabine cells with the IC50 of gemcitabine as the drug concentration.The relative expression levels of Hippo/YAP pathway-related proteins(MST1/2,LAST1/2,YAP,p-YAP)were detected by immunoblotting(WB).Results Compared with 0 mmol/L Met,the survival rates of CFPAC-1 and CFPAC-1/GEM cells treated with 10.0,20.0 and 40.0 mmol/L Met were significantly decreased,the differences were statistically significant(F=15.632,20.958;all P<0.001).With the increase of GEM concentration,the survival rate of CFPAC-1 and CFPAC-1/GEM cells decreased,the IC50 of CFPAC-1/GEM cells against GEM[(93.35±5.12)µmol/L vs.(217.87±11.34)μmol/L]was significantly higher than that of CFPAC-1 cells,the difference was statistically significant(t=24.514,P<0.05),and the drug resistance index of CFPAC-1/GEM cells was 2.33.The IC50(76.53±3.65)µmol/L of CFPAC-1 cells treated with 2.5 mmol/L Met combined with different concentrations of GEM was lower than that treated with GEM alone(93.35±5.12)μmol/L(t=6.552,P<0.05).The IC50 of CFPAC-1/GEM cells(171.65±6.89)μmol/L was lower than that of GEM alone(217.87±11.34)μmol/L(t=8.532,P<0.05),and the reversion multiple of CFPAC-1/GEM cell to GEM was 1.26.Compared with the GEM group,the apoptosis rate of CFPAC-1/GEM cells,the expression of MST1/2,LAST1/2 and p-YAP/YAP were significantly increased,the differences were statistically significant(F=53.798,35.585,14.512,25.525;all P<0.001).Conclusion Met could increase the chemotherapy sensitivity of CFP-1/GEM cells to GEM to some extent,which might be related to the activation of Hippo/YAP pathway.

Pancreatic cancerMetforminGemcitabineHippo/YAP pathway

赛米热·艾斯拉、木则帕尔·太来提、艾尔夏提·依布拉音、布热米古丽·买买提、努尔比叶·艾力

展开 >

喀什地区第一人民医院药学部,新疆喀什 844000

喀什地区第一人民医院普外科,新疆喀什 844000

胰腺癌 二甲双胍 吉西他滨 Hippo/YAP通路

新疆维吾尔自治区卫生健康青年科技人才专项

WJWY-202102

2024

热带医学杂志
广东省寄生虫学会 中华预防医学会

热带医学杂志

CSTPCD
影响因子:0.643
ISSN:1672-3619
年,卷(期):2024.24(7)
  • 9